Bayer's Sunharbo Approval Introduces a New Class of Secondary Stroke Prevention Therapy

November 12, 2026

Bayer has received US Food and Drug Administration (FDA) approval for Sunharbo (asundexian), a once-daily oral factor XIa (FXIa) inhibitor designed to reduce the risk of recurrent ischemic stroke in selected adults.

The approval, announced on November 9, 2026, introduces the first FDA-approved factor XIa inhibitor in the United States. Sunharbo is indicated alongside antiplatelet therapy for adults following a recent non-cardioembolic ischemic stroke or high-risk transient ischemic attack (TIA).

The approval represents an important development in secondary stroke prevention, where clinicians need to reduce recurrent clot-related events without substantially increasing bleeding complications.

Bayer's regulatory achievement follows China's approval of asundexian on October 26, 2026, making China the first country to authorise this new treatment class.

Towards Healthcare Provides Platform where You can Publish Your Articles/Blogs/Press Releases/Announcements Easily. Publish Your PR and Get Genuine Traffic and Engagement: https://www.towardshealthcare.com/guest-post-placement#content-guideline 

Why Factor XIa Inhibition Matters in Stroke Prevention

Ischemic stroke occurs when a blood clot blocks blood flow to part of the brain. It accounts for the majority of stroke cases and can lead to permanent neurological damage, disability or death.

Patients who survive an initial ischemic stroke remain at risk of another event. Existing secondary prevention strategies include antiplatelet medicines, anticoagulants for specific indications, cholesterol-lowering treatments and management of conditions such as hypertension and diabetes.

However, balancing clot prevention with bleeding risk remains a major clinical challenge.

Factor XIa is an activated protein in the intrinsic coagulation pathway. It contributes to thrombin generation and the formation of blood clots.

Asundexian selectively inhibits factor XIa, reducing amplification of thrombin generation. The scientific rationale is that inhibiting this pathway may reduce pathological thrombosis while having a more limited effect on normal haemostasis than some conventional anticoagulant approaches.

This mechanism has made factor XIa an important target in pharmaceutical research, particularly for patients who need additional protection against thrombotic events.

FDA Approval and Treatment Indication

The FDA approved Sunharbo 50 mg tablets for use in combination with antiplatelet therapy to reduce stroke risk in adults with:

• A recent non-cardioembolic ischemic stroke with a National Institutes of Health Stroke Scale (NIHSS) score of 15 or lower.

• A recent high-risk transient ischemic attack.

The recommended dosage is 50 mg orally once daily, with or without food.

The medicine is not approved for stroke prevention in patients with atrial fibrillation. Its indication is also not intended to replace standard acute stroke treatment or emergency intervention.

The FDA granted Sunharbo Fast Track and Priority Review designations before approval, reflecting the importance of developing additional treatment options for secondary stroke prevention. <Cite refs={["turn490549search0","turn490549search36"]}/>

OCEANIC-STROKE Phase III Trial: Key Clinical Findings

The FDA approval was supported by the Phase III OCEANIC-STROKE trial (NCT05686070), which evaluated asundexian in patients following a recent non-cardioembolic ischemic stroke or high-risk TIA.

The international, randomised, double-blind, placebo-controlled trial enrolled 12,327 participants.

Patients received either asundexian 50 mg once daily or placebo, alongside antiplatelet therapy. The primary efficacy endpoint was the occurrence of ischemic stroke.

Major Clinical Results

26% reduction in ischemic stroke: Asundexian reduced the relative risk of ischemic stroke by 26% compared with placebo. The hazard ratio was 0.74, with a 95% confidence interval of 0.65 to 0.84.

Similar major bleeding rates: Major bleeding occurred in 1.9% of patients receiving asundexian and 1.7% receiving placebo. The difference was not statistically significant.

Reduction in all strokes: The treatment also reduced the occurrence of all strokes, including ischemic and hemorrhagic events, from 8.8% to 6.6%.

Cardiovascular outcomes: The composite of cardiovascular death, myocardial infarction or stroke occurred in 9.2% of the asundexian group compared with 11.1% of the placebo group.

The trial followed participants for a median of 19 months, providing evidence of treatment effects beyond the initial post-stroke period. <Cite refs={["turn490549search4","turn490549search1","turn490549search7"]}/>

Understanding the Bleeding Results

The bleeding findings are particularly important because adding an anticoagulant-pathway inhibitor to antiplatelet treatment raises concerns about additional bleeding risk.

Although overall major bleeding rates were similar, the trial reported more gastrointestinal bleeding with asundexian.

Any gastrointestinal bleeding occurred at rates of 3.0% with asundexian and 2.4% with placebo. Lower gastrointestinal bleeding was also more frequent in the treatment group.

Therefore, the results should be interpreted as a reduction in ischemic stroke without a statistically significant increase in major bleeding, rather than an absence of bleeding risk. <Cite refs={["turn490549search2","turn490549search4"]}/>

Global Regulatory Milestone

Bayer's regulatory progress in 2026 gives asundexian an early position in the factor XIa inhibitor category.

China: China's National Medical Products Administration approved asundexian on October 26, 2026, for reducing stroke risk following non-cardioembolic ischemic stroke or high-risk TIA. This was the first global regulatory approval for a factor XIa inhibitor.

United States: The FDA approved Sunharbo on November 9, 2026, making it the first factor XIa inhibitor authorised in the US.

Europe and Japan: As of November 2026, Bayer reported that asundexian remained under review by the European Medicines Agency and Japan's Ministry of Health, Labour and Welfare.

These approvals and reviews create a foundation for international commercial expansion, although reimbursement, prescribing requirements and local regulatory decisions will differ across countries. <Cite refs={["turn490549search1","turn490549search6"]}/>

Competitive Landscape: Bayer Versus Other Factor XIa Developers

Bayer currently has a regulatory advantage in this treatment category. However, other pharmaceutical companies are developing factor XIa inhibitors for cardiovascular and cerebrovascular conditions.

1. Bayer: Sunharbo (Asundexian)

Bayer has moved asundexian from clinical development into commercialisation for secondary stroke prevention.

Its Phase III OCEANIC-STROKE results demonstrated a 26% reduction in ischemic stroke compared with placebo, alongside similar overall major bleeding rates.

The approval provides Bayer with an opportunity to establish the clinical and commercial position of factor XIa inhibition in a defined stroke population.

2. Bristol Myers Squibb and Johnson & Johnson: Milvexian

Bristol Myers Squibb (BMS) and Johnson & Johnson (J&J) are developing milvexian, another oral factor XIa inhibitor.

The companies are evaluating the drug across several thrombotic conditions through the LIBREXIA clinical development programme.

For secondary stroke prevention, the Phase III LIBREXIA-STROKE trial (NCT05702034) evaluated milvexian against placebo in patients following an acute ischemic stroke or high-risk TIA.

The trial enrolled approximately 12,523 participants and completed its planned study period in October 2026. Publicly available trial information in November 2026 did not yet provide definitive efficacy results.

The outcome will be important for assessing whether another factor XIa inhibitor can demonstrate clinical benefit in secondary stroke prevention. <Cite refs={["turn251324search0","turn251324search10","turn251324search12"]}/>

Competitive Comparison

Bayer currently has the first approved product in this category in the United States. Milvexian remains an investigational competitor for this indication.

The two products should not be compared on efficacy until the relevant clinical data are available.

Bayer's Commercial Strategy and Growth Opportunities

Sunharbo gives Bayer an opportunity to expand its cardiovascular and cerebrovascular portfolio through a new treatment mechanism.

However, regulatory approval is only the first step. Commercial adoption will depend on clinical confidence, reimbursement, physician education and patient access.

1. Neurologist and Stroke Centre Adoption

Neurologists, stroke specialists and hospital-based physicians will be central to the adoption process.

Bayer will need to communicate the clinical evidence, approved patient population, dosing requirements and safety considerations to healthcare professionals.

Stroke centres and specialist hospitals are likely to be important stakeholders in early product adoption.

2. Differentiation Through Clinical Evidence

The OCEANIC-STROKE findings provide Bayer with a strong basis for positioning Sunharbo.

The reduction in recurrent ischemic stroke, combined with similar overall major bleeding rates, represents an important clinical consideration.

Longer-term evidence and real-world treatment outcomes will help establish how the medicine performs in routine clinical practice.

3. Reimbursement and Market Access

Access will depend on payer decisions, hospital formularies, prescribing guidelines and the economic value demonstrated by the treatment.

Bayer will need to establish the role of Sunharbo alongside existing antiplatelet therapies and secondary prevention strategies.

4. International Commercial Expansion

China and the United States have approved asundexian, while regulatory reviews in Europe and Japan create additional expansion opportunities.

Different healthcare systems will require local commercial strategies, pricing assessments, reimbursement planning and physician engagement.

5. Competition Within the FXIa Drug Class

The approval creates a new commercial category for factor XIa inhibitors.

As other candidates progress through clinical development, companies will need to differentiate their products through efficacy, bleeding outcomes, dosing convenience, patient selection and long-term safety.

Challenges and Risks for Bayer

Despite the positive clinical results, several factors could influence Sunharbo's commercial performance.

• Bleeding considerations: Gastrointestinal bleeding and other adverse events require appropriate clinical assessment.

• Patient selection: The approved indication is limited to specific non-cardioembolic stroke and high-risk TIA populations.

• Clinical positioning: Physicians must determine how the medicine fits alongside established antiplatelet and secondary prevention approaches.

• Competitor development: Milvexian and other investigational FXIa inhibitors could create future competition.

• Long-term evidence: Additional real-world data will help clarify treatment persistence, safety and effectiveness across broader patient populations.

The commercial opportunity will depend on whether Bayer can translate the Phase III results into sustained physician adoption and broad patient access.

What This Approval Means for the Pharmaceutical Industry

Sunharbo's approval highlights several important developments in cardiovascular drug research.

A new therapeutic target: Factor XIa inhibition introduces another approach to reducing thrombotic events and expands the range of targets being investigated in coagulation research.

Secondary prevention innovation: The approval addresses patients who remain at risk of recurrent ischemic stroke despite established preventive treatment strategies.

Competition in anticoagulant development: The development programmes of Bayer, BMS and J&J demonstrate continued pharmaceutical investment in alternative coagulation pathways.

Clinical evidence as a commercial differentiator: Demonstrating fewer recurrent ischemic events without a statistically significant increase in major bleeding can be important for physician confidence and market access.

How Towards Healthcare Supports Cardiovascular Drug Decision-Makers

Towards Healthcare provides strategic intelligence to pharmaceutical companies, biotechnology organisations and investors assessing cardiovascular drug development and competitive opportunities.

Our capabilities include:

• Complete Master Datasets: Company profiles, drug pipelines, clinical trials and product intelligence.

• Competitive Quadrants: Assessment of cardiovascular drug developers and their competitive positioning.

• Customized Dashboards: Tracking of clinical milestones, regulatory approvals and company developments.

• Pipeline Intelligence: Monitoring of investigational therapies, trial progress and emerging mechanisms.

• Buyer Identification: Identification of relevant pharmaceutical, healthcare and clinical stakeholders.

• GTM Strategy: Assessment of therapeutic opportunities, regional expansion and commercial positioning.

Conclusion

Bayer's FDA approval of Sunharbo introduces the first US-approved factor XIa inhibitor and establishes a new treatment option for secondary stroke prevention in selected adults.

The OCEANIC-STROKE trial demonstrated a 26% relative reduction in ischemic stroke compared with placebo, with similar overall major bleeding rates. These findings provide an important clinical foundation for the treatment's commercial launch.

Bayer now faces the challenge of building physician adoption, securing reimbursement and establishing the role of Sunharbo alongside existing stroke prevention therapies.

For the wider pharmaceutical industry, the approval represents an important milestone in factor XIa drug development and creates a new competitive category for cardiovascular and cerebrovascular medicines.

Explore cardiovascular drug pipelines, clinical trial developments and pharmaceutical competitive intelligence with Towards Healthcare.

Contact: [email protected]